key: cord-0959588-kils4qbz
authors: Hoek, Rogier A.S.; Manintveld, Olivier C.; Betjes, Michiel G.H.; Hellemons, Merel E.; Seghers, Leonard; van Kampen, Jeroen A.A.; Caliskan, Kadir; van de Wetering, Jacqueline; van den Hoogen, Martijn; Metselaar, Herold J.; Hesselink, Dennis A.
title: Covid‐19 in solid organ transplant recipients: A single center experience
date: 2020-05-27
journal: Transpl Int
DOI: 10.1111/tri.13662
sha: fbc73cae00ef010a0dcff2e49f34f705c643bb0f
doc_id: 959588
cord_uid: kils4qbz

BACKGROUND: Solid organ transplant (SOT) recipients may be at risk for severe COVID‐19. Data on the clinical course of COVID‐19 in immunosuppressed patients are limited and the effective treatment strategy for these patients is unknown. METHODS: We describe our institutional experience with COVID‐19 in SOT. Demographic, clinical and treatment data were extracted from the electronic patient files. RESULTS: A total of 23 SOT transplant recipients suffering from COVID‐19 were identified (n = 3 heart; n =15 kidney; n = 1 kidney‐after‐heart; n = 3 lung and n = 1 liver transplant recipient). The presenting symptoms were similar to non‐immunocompromised patients Eighty‐three percent (19/23) of the patients required hospitalization but only two of these were transferred to the intensive care unit. Five patients died from COVID‐19; all had high Clinical Frailty scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only 3 patients were treated with chloroquine. Most patients recovered without experimental anti‐viral therapy. CONCLUSIONS: Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID‐19. Pre‐existent frailty is associated with death from COVID‐19.

The first case of corona virus disease 2019 was diagnosed in December 2019 in Wuhan, China. [1] [2] [3] Since then, this novel infectious disease, which is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has grown into a pandemic with over 4 million infected individuals worldwide (https://who.sprinklr.com/; accessed May 14 th , 2020). [1] [2] [3] Various compounds with presumed anti-viral activity are now being tested in clinical trials but at present there is no demonstrated effective therapy other than supportive care. [4] [5] [6] [7] [8] [9] [10] Solid organ transplant (SOT) recipients are perceived to be at increased risk for severe COVID-19 because of their chronic immunosuppressed state. However, there are indications that severe COVID-19 results from a hyper-inflammatory state and that immunosuppressive therapy may even be beneficial in selected cases as it may mitigate lung inflammation. 11 Data on SOT recipients suffering from COVID-19 are scarce and only a few cases have been reported in the English literature. [12] [13] [14] [15] [16] [17] [18] [19] Most of these patients had symptoms that were comparable to those of the general population affected by COVID-19.

Several interventions were followed in these SOT recipients with COVID-19, including reduction and withdrawal of immunosuppression, high-dose glucocorticoids, and treatment with experimental anti-viral agents including chloroquine, lopinavir/ritonavir, remdesivir and umifenovir. [12] [13] [14] [15] [16] [17] [18] [19] Here, we report 23 SOT recipients with COVID-19 from a single-institution and describe the clinical outcomes and the treatments that were instituted.

All SOT recipients who were diagnosed with COVID-19 in our center or in one of the local referring hospitals since the first case was diagnosed in the Netherlands ( 

This article is protected by copyright. All rights reserved performed on an annual basis. Patients were identified from the transplant database of the departments of Pulmonary Medicine (n=175 lung transplant recipients), Cardiology (n=306 heart transplant recipients), Hepatology (n=950 liver transplant recipients) and Nephrology (n=2150 kidney transplant recipients) or after consultation by local medical specialists. We included all cases until April 30 th , 2020.

A diagnosis of COVID-19 was made whenever a patient had typical symptoms (either a temperature >38˚C, cough, rhinitis, dyspnea or a combination of these) and PCR testing of a throat and nasal swab was positive for SARS-CoV-2. Only patients with reported complaints were tested; no pre-emptive testing was performed.

Of all patients, demographic data, clinical and laboratory parameters, radiological findings, treatment data (use of antiviral drugs, use of experimental antiviral therapy, modification of immunosuppression) were collected from the electronic patient files.

Disease severity was scored from mild to critical for all patients. 20, 21 Health status of patients was scored by using the Canadian Study of Health and Aging (CSHA) Clinical Frailty Scale (CFS). 22 The medical ethical review board of our hospital approved collection of clinical data in COVID-19 patients. Furthermore, all SOT recipients in our institution provided written informed consent for collection of clinical data as part of an ongoing quality improvement program.

A total of 23 SOT recipients were identified: 15 kidney (10 living donor; 5 deceased donor), 4 heart, 3 lung, 1 kidney-after-heart (living donor kidney) and 1 liver transplant recipient.

( Table 1 ). The first case was diagnosed with COVID-19 on March 12, 2020, 15 days after the first case was diagnosed in the Netherlands. Fourteen recipients were Caucasian, 6

were of African ethnicity, 2 were Latin-American and 1 was of Asian descent. Eighteen patients (78%) were male and patients had a mean age of 59 years (range 21-81). Most patients presented with typical symptoms, including fever (81%), cough (71%) and dyspnea

This article is protected by copyright. All rights reserved (59%; Table 2 ). Three renal transplant patients had symptoms consistent with concomitant urinary tract infection and three patients had diarrhea. Only one patient was in his first postoperative year after transplantation. All 23 patients had a baseline immunosuppressive regimen consisting of a calcineurin inhibitor, combined with either mycophenolate mofetil (MMF; n = 14), MMF plus prednisolone (n = 6), prednisolone alone (n = 1) or everolimus (ERL; n = 1).

Three patients only had mild disease and were monitored at home without additional treatment. For one frail patient it was decided to provide best supportive care at home. The majority of patients (19 out of 23) was hospitalized and all of these received broad-spectrum antibiotic therapy to treat possible bacterial pneumonia or suspected urinary tract infection.

The median length of stay in the hospital was 10 days (range 3-21) Laboratory results on admission are shown in Table 2 . All hospitalized patients had chest radiographs consistent with viral pneumonia. In 13 of the 23 patients, no change in immunosuppressive treatment was made. In the other 10 SOT recipients, MMF or ERL were reduced or withdrawn ( Table   2 ). Three heart transplant recipients received a 5-day course of chloroquine. The other 17 patients did not receive any anti-viral therapy ( Table 2) . and two had type 2 diabetes mellitus. Because of their poor physical status, a decision was made not to transfer these three kidney transplant recipients to the ICU but to provide best supportive care.

Mortality was highly correlated with CFS. Patients who died from COVID-19 had a mean CFS of 5.8 compared to 1.92 for survivors. Moreover, among the 10 patients who were treated with a reduction of their immunosuppression because of moderate to severe COVID-19, survivors (n = 7) had a mean CFS of 2.3 compared to 6.0 for non-survivors (n = 3). The length of hospital stay in this group was higher (14.7; range 14-39 days) compared to the group that did not receive a reduction of immunosuppression (8.2; range 3-16 days).

Also, mortality was higher in the group that received a reduction of immunosuppression (30% versus 15.4%).

Here, 23 SOT recipients from a single center who were diagnosed with COVID-19 are reported. The majority of these patients (83%) required hospitalization but unlike previously reported cases 2,12-19 , most of our patients suffered from moderately severe disease which only required supportive treatment with oxygen. In addition, in 10 patients, a decision was made to stop or reduce the dose of the anti-proliferative agents. Of note is that in this cohort there was only one patient with COVID-19 who was in his first transplant year. We can only speculate on the role of (high-dose) immunosuppression in this group on the development of severe COVID-19. The CFS correlated with poor outcome and was higher in non-survivors compared with survivors. A correlation between outcome and CFS was reported previously for ICU patients. 23 Apart from three heart transplant recipients, none of the other SOT recipients was treated with drugs with presumed antiviral activity. Most of the hospitalized patients were treated with azithromycin, which may have contributed to the relatively mild COVID-19 course in the majority of patients. It has been suggested that macrolide antibiotics have an

This article is protected by copyright. All rights reserved immunomodulatory effect on neutrophil-, macrophage-and lymphocytic activity, leading to a reduced inflammatory response and increased production of anti-inflammatory mediators. [24] [25] [26] While MMF has reported in vitro anti-viral properties, clinical studies do not suggest a benefit in coronavirus infection and even possible harm. 27 Therefore, in more severe disease, we stopped MMF. In the group of patients in whom the immunosuppression was reduced, the length of hospital stay and mortality were higher, which probably related to the higher disease severity at presentation. Tacrolimus has anti-viral properties against coronaviruses in vitro but no human studies have been performed to date. 28, 29 Therefore, the tacrolimus dose was not changed, except in one patient in whom the trough concentration was above target. Potentially, immunosuppressive medication may mitigate the viral replication or the immune response, modifying disease outcome. Transplant activity during the COVID-19 pandemic was negatively affected at our center due to decreased organ donation numbers and prioritization of heath care services for severe COVID-19 patients. 30 Living donor transplantation activity was temporarily put on hold for kidney transplantation and deceased donor activity was limited to medically urgent and highly-immunized patients only. The liver-heart-and lung transplantation programs continued where possible but experienced a marked decline in transplantations.

This article is protected by copyright. All rights reserved Five (or 22%) of our patients died from COVID-19. In the Netherlands, there have been 5,562 confirmed deaths from COVID-19 but this is likely an underestimation (source https://www.rivm.nl/coronavirus-covid-19/actueel; accessed May 14 th , 2020). The mortality rate in the present series appears to be higher than the 12.9% death rate in the general Dutch population.

To the best of our knowledge, this is one of the first series of patients with COVID-19 after various types of SOT. We believe our observations are of interest as they demonstrate that immunosuppressed patients suffering from COVID-19 and who have a frail phenotype are at risk for poor outcome. Also, in patients with low CFS, adaptation of their immunosuppressive regimen only and without the administration of potentially toxic and as yet unproven antiviral therapy is a therapeutic option. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A novel coronavirus from patients with pneumonia in China

Global transplantation COVID report

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus disease

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Care for critically ill patients with COVID-19

Management of critically ill adults with COVID-19

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

COVID-19: consider cytokine storm syndromes and immunosuppression

Accepted Article This article is protected by copyright. All rights reserved 12

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation?

COVID-19 in posttransplantation patients: report of two cases

First cases of COVID-19 in heart transplantation from

Perioperative presentation of COVID-19 disease in a liver transplant recipient

Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient

COVID-19 in a lung transplant Recipient

Covid-19 and Kidney Transplantation

Characteristics of and Important Lessons From the

COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Mild or Moderate Covid-19

A global clinical measure of fitness and frailty in elderly people

Accepted Article This article is protected by copyright. All rights reserved 23

Frailty and Subsequent Disability and Mortality among Patients with Critical Illness

Effect of 14-membered macrolide compounds on monocyte to macrophage differentiation

Azithromycin alters macrophage phenotype

Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis

A review of treatment modalities for Middle East Respiratory Syndrome

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

Immediate impact of COVID-19 on transplant activity in the Netherlands

This article is protected by copyright. All rights reserved 

Abbreviations: ARI: acute respiratory infection; SpO2: peripheral oxygen saturation; IS:immunosuppression; CRP: C-reactive protein; PCT: procalcitonin; ICU: intensive care unit;RRT: renal replacement therapy